- \n
- \nIncreased cutting speed of 25,000 cuts per minute1<\/sup> is designed to minimize retinal traction,2<\/sup> increase vitreous flow,1<\/sup> and reduce infusion pressure fluctuations when used with Adaptive Fluidics.3*<\/sup><\/li>\n
- \nBi-Blade+ provides an average flow rate increase of 25%, enabling more efficient vitreous removal compared to Bi-Blade\u00ae<\/sup>.1*\u2020<\/sup><\/li>\n
- \nThe resulting stability, efficiency and control help boost confidence for retina surgeons to deliver exceptional patient outcomes.<\/p>\n<\/li>\n<\/ul>\n
VAUGHAN, Ontario–(BUSINESS WIRE<\/a>)–
\nBausch + Lomb Corporation (NYSE\/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance for the Bi-Blade+ advanced dual-port vitrectomy cutter and the Adaptive Fluidics advanced update on the Stellaris Elite\u00ae<\/sup> Vision Enhancement System.<\/p>\nThis press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260408564994\/en\/<\/a><\/p>\n
![\"\"](\"https:\/\/mms.businesswire.com\/media\/20260408564994\/en\/2767711\/4\/BiBlade_Plus_Product_Image_Group.jpg\")
<\/div>\n\n\u201cRetinal surgeons who are familiar with our Bi-Blade technology understand the benefits of its dual-port design, 100% open duty cycle and cutting speed of 15,000 cuts per minute,\u201d said Wayne Caulder, vice president and general manager, North America Surgical, Bausch + Lomb. \u201cBi-Blade+ offers these features along with an increased cutting speed of 25,000 cuts per minute. When combined with Adaptive Fluidics, surgeons will experience stability, efficiency and control that will help streamline procedures and deliver exceptional patient outcomes.\u201d<\/p>\n
\nBi-Blade+ provides an increased flow rate of 25%, enabling more efficient vitreous removal compared to Bi-Blade.1*<\/sup> At maximum speed, Bi-Blade+ also demonstrates a 62% reduction in cutter vibration compared to Bi-Blade, offering the surgeon optimized feel and comfort toward a stable surgical experience.4<\/sup><\/p>\n
\nThe Adaptive Fluidics update automates fluid infusion to the eye in response to real-time vacuum commands from the surgeon, delivering precise and responsive fluidics infusion at every step of a vitrectomy procedure.<\/p>\n
\nThese two technologies combine to support and maintain IOP stability and control. When combined with Adaptive Fluidics, Bi-Blade+ demonstrated a 62% reduction in average infusion pressure compared to surgeries in which Adaptive Fluidics was not used.3<\/sup> Continuous aspiration also provides consistent intraocular pressure (IOP) stability.3**<\/sup> In one study, use of Bi-Blade+ with Adaptive Fluidics resulted in a significant improvement in chamber IOP at a range closer to physiologic IOP (10 \u2013 20 mmHg) even during high vacuum levels.3***<\/sup><\/p>\n
\n\u201cBi-Blade has been an essential tool for me in a variety of surgeries, including core vitrectomies, vitreous shaving near mobile retina, removal of intraocular tissues and dissections,\u201d said Professor Marco Mura, MD, University of Ferrara, Ferrara, Italy. \u201cThe increased cut speed that Bi-Blade+ offers paired with the additional control of Adaptive Fluidics promises to further promote stability and efficiency during surgery.\u201d<\/p>\n
\n
\n \n \n*Based on bench and animal testing.<\/p>\n<\/td>\n<\/tr>\n
\n \n \n** Based on bench testing.<\/p>\n<\/td>\n<\/tr>\n
\n \n \n***Based on bench testing comparing original Bi-Blade to single-port cutter.<\/p>\n<\/td>\n<\/tr>\n
\n \n \n\u00a0<\/p>\n<\/td>\n<\/tr>\n
\n \n \u2020<\/sup>Bi-Blade\u00ae<\/sup> is a trademark of Medical Instrument Development Laboratories, Inc. and is used by Bausch + Lomb under license.<\/p>\n<\/td>\n<\/tr>\n<\/table>\n
Bi-Blade\u2122+ Indications and Important Safety Information<\/b><\/p>\n
Indications and Intended Use<\/b>: The Bausch + Lomb vitrectomy cutter pouches are intended to cut and remove vitreous from the eye. They are indicated for any ocular condition requiring anterior vitrectomy during anterior segment surgery and for any vitreoretinal condition requiring vitrectomy during posterior or combined surgery.<\/p>\n
Compatible Equipment: <\/b>Stellaris Elite Bi-Blade+ accessories are only intended to operate with Bausch + Lomb Stellaris Elite vision enhancement systems with Bi-Blade+ procedure pack compatibility.<\/p>\n
Known residual risks and complications<\/b> include but are not limited to: infection; inflammation; ocular damage; trauma; cataract formation (not applicable in cataract removal procedures); foreign body\/particulates in eye; intraocular pressure (IOP) variance that may cause damage to patient\u2019s eye; visual impairment; ischemia; allergic reaction; edema.<\/p>\n
ATTENTION<\/b>: See the Instructions for Use for detailed directions, proper use, and full risk and safety information.<\/p>\n
CAUTION<\/b>: Federal (U.S.) Law restricts this device to sale, by or on the order of a physician.<\/p>\n
About Bausch + Lomb<\/b><\/p>\n
\nOur mission is simple \u2013 we help people see better to live better, all over the world. For nearly two centuries we\u2019ve evolved with the changing needs of patients and customers, and our commitment to innovation and improving the standard of care in eye health has never been stronger. From contact lenses to prescription products, over-the-counter options, surgical devices and more, we\u2019re turning bold ideas into better outcomes through passion, perseverance and purpose. Learn more at www.bausch.com<\/a> and connect with us on Facebook<\/a>, Instagram<\/a>, LinkedIn<\/a>, X<\/a> and YouTube<\/a>.<\/p>\n
Forward-looking Statements<\/b><\/p>\n
\nThis news release may contain forward-looking information and statements within the meaning of applicable securities laws (collectively, \u201cforward-looking statements\u201d). Forward-looking statements may generally be identified by the use of the words \u201canticipates,\u201d \u201cseeks,\u201d \u201cexpects,\u201d \u201cplans,\u201d \u201cshould,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cmay,\u201d \u201cwill,\u201d \u201cbelieves,\u201d \u201cpotential,\u201d \u201cpending\u201d or \u201cproposed\u201d and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch + Lomb\u2019s filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch + Lomb undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.<\/p>\n
- \nBi-Blade+ provides an average flow rate increase of 25%, enabling more efficient vitreous removal compared to Bi-Blade\u00ae<\/sup>.1*\u2020<\/sup><\/li>\n
![\"Photo\"](\"https:\/\/mms.businesswire.com\/media\/20260408564994\/en\/2767711\/3\/BiBlade_Plus_Product_Image_Group.jpg\")
<\/td>\n<\/tr>\n![\"Logo\"](\"https:\/\/mms.businesswire.com\/media\/20260408564994\/en\/1668940\/3\/Bausch_Lomb_logo.jpg\"){kind=logo}
<\/td>\n<\/tr>\n